RecruitingNCT05200429

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

Canadian Observational Study Evaluating the Long-term IMPACT of CFTR (Can-IMPACT CF)


Sponsor

University of British Columbia

Enrollment

500 participants

Start Date

Nov 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This observational study intends to investigate health trends and data in cystic fibrosis patients all across Canada that are receiving modulator treatment so researchers can determine if CFTR treatments are effective over a long period of time and if so, which treatments work best for each individual. The study will collect clinical data from routine standard of care, patient reported outcomes via survey data and samples for a biobank.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Trikafta for people with cystic fibrosis. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrikafta

Highly Effective CFTR Modulator Therapy


Locations(2)

British Columbia Children's Hospital

Vancouver, British Columbia, Canada

St Paul's Hospital

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05200429


Related Trials